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Alternative splicing discriminates molecular subtypes and has
prognostic impact in diffuse large B-cell lymphoma
S-K Leivonen1,2,6, M Taskinen1,2,6, A Cervera1, M-L Karjalainen-Lindsberg3, J Delabie4,7, H Holte5, R Lehtonen1, S Hautaniemi1
and S Leppä1,2
Effect of alternative splicing (AS) on diffuse large B-cell lymphoma (DLBCL) pathogenesis and survival has not been systematically
addressed. Here, we compared differentially expressed genes and exons in association with survival after chemoimmunotherapy,
and between germinal center B-cell like (GCB) and activated B-cell like (ABC) DLBCLs. Genome-wide exon array-based screen was
performed from samples of 38 clinically high-risk patients who were treated in a Nordic phase II study with dose-dense
chemoimmunotherapy and central nervous system prophylaxis. The exon expression profile separated the patients according to
molecular subgroups and survival better than the gene expression profile. Pathway analyses revealed enrichment of AS genes in
inflammation and adhesion-related processes, and in signal transduction, such as phosphatidylinositol signaling system and
adenosine triphosphate binding cassette transporters. Altogether, 49% of AS-related exons were protein coding, and domain
prediction showed 28% of such exons to include a functional domain, such as transmembrane helix domain or phosphorylation
sites. Validation in an independent cohort of 92 DLBCL samples subjected to RNA-sequencing confirmed differential exon usage of
selected genes and association of AS with molecular subtypes and survival. The results indicate that AS events are able to
discriminate GCB and ABC DLBCLs and have prognostic impact in DLBCL.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common
lymphoid neoplasm in adults, comprising 30–40% of all malignant
lymphomas. It is an aggressive disease, where ∼ 60% of patients
can be cured with a combination of rituximab and anthracycline-
based CHOP or CHOP-like chemoimmunotherapy.1,2 However,
responses to treatment are still largely unpredictable, and survival
of the patients, who experience disease relapse or have primary
refractory disease, is dismal. Thus, there is a growing need to
further understand the molecular mechanisms underlying the
disease that would not only provide information to predict the
survival, but also enable the design of more targeted therapeutic
strategies.
Based on gene expression profiling, three molecular subtypes
showing germinal center B-cell (GCB), activated B-cell (ABC) and
primary mediastinal B-cell lymphoma signatures have been
identified. These subtypes differ in their genotypic, phenotypic
and clinical features.3–6 During the past few years, studies
applying next-generation sequencing techniques have provided
further insights into the heterogeneity and pathogenesis of
DLBCL.7–9 Especially, a number of genetic alterations have been
shown to be characteristic of GCB or ABC subtypes. However,
despite the rapidly growing number of genetic aberrations
reported in DLBCL, association of these findings with treatment
outcome remains to be shown.
Alternative splicing (AS) is a common regulatory mechanism
generating multiple RNA transcripts from a single gene and
allowing enormous functional diversity in protein isoforms. The
vast majority of the human genes, evaluates ranging from 70 to
95%, are alternatively spliced.10 Growing evidence suggests that
AS is closely associated with cancer pathogenesis and
progression.11–13 Alternatively spliced signatures derived from
gene expression profiling have been shown to be more reliable for
diagnostic purposes than signatures derived from expression
profiling, for example in prostate cancer.14 Furthermore, isoform-
level expression profiles can discriminate cancer cell lines from
noncancer cells better than gene-level expression profiles.15
In DLBCL, the role of AS remains largely unexplored. Previous
studies have mainly focused on AS isoforms of individual genes,
such as FOXP1, where contradictory findings concerning its
prognostic role can partly be explained by smaller and potentially
oncogenic FOXP1 isoforms primarily expressed in ABC-type
DLBCL.16 Other previously reported genes with AS in DLBCL
include a developmentally regulated B-lymphoid phosphatase,
PTPRO, regulating G0/G1 arrest
17 and a leukocyte homing and
hyaluronidase receptor CD44.18–21
In this study, we have evaluated genome-wide gene and exon
expression profiles in DLBCL. Differential exon usage was found to
be a common event in DLBCL. Splicing events affected pivotal
genes involved in DLBCL signaling, and were able to discriminate
the patients according to cell of origin (COO) and survival.
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Prospectively collected discovery cohort consisted of 38 DLBCL patients
o65 years old with clinically high-risk (age-adjusted International
Prognostic Index Score 2–3) disease (Table 1). The patients were treated
in a Nordic phase II NLG-LBC-04 protocol with six courses of dose-dense
R-CHOEP-14 chemoimmunotherapy followed by systemic central nervous
system prophylaxis with high-dose methotrexate and high-dose
cytarabine.22 Further information on the patient cohort is provided in
the Supplementary Materials and methods. The protocol and sampling
were approved by Institutional Review Boards, National Medical Agencies
and Ethics Committees in Finland, Denmark, Sweden and Norway, and the
trial was registered at ClinicalTrials.gov, identifier number NCT01502982.
All patients gave informed consent.
Validation cohort consisted of RNA sequencing (RNAseq) and clinical
data from 92 R-CHOP-like chemotherapy-treated DLBCL patients gener-
ated by the National Cancer Institute (NCI) Cancer Genome Characteriza-
tion Initiative (CGCI; dbGaP database applied study accession: phs000532.
v3.p1)7,8 (Table 1).
Samples and gene/exon expression analysis
Total RNA was extracted with Qiagen (Hilden, Germany) AllPrep DNA/RNA/
Protein Mini kit and examined using Affymetrix Human Exon 1.0 ST arrays
according to the manufacturer’s instructions (Affymetrix, Santa Clara, CA,
USA). Hybridization protocols and raw expression microarray data are
available at ArrayExpress archive (http://www.ebi.ac.uk/arrayexpress/experi
ments/E-MEXP-3488). Gene- and exon-level expression data for the NLG-
LBC-04 discovery cohort were quantified by MEAP (Multiple Exon Array
Preprocessing) algorithm23 with MEAP probe annotation version 70.
In the CGCI validation cohort, adaptors and low-quality bases were
trimmed from the samples before alignment. The reads were aligned with
TopHat 2.0.8b using the hg19 human reference genome with Ensembl
gene annotation version 70. HTSeq was then used to obtain the exon- and
gene-level read counts. Differential expression at exon and gene levels was
estimated using DEXSeq (version 1.7.14) and DESeq2 (version 1.4.5),
respectively (https://bioconductor.org/packages/3.5/bioc/).
Molecular subgroup prediction
Samples with exon array data were classified into GCB, ABC and
nonclassified subgroups using the gene predictor from Lymphochip data
as previously described.24 More details are provided in the Supplementary
Materials and methods.
Pathway and GO analysis
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway functional
enrichment analyses were performed with the Pathway-Express (Intelligent
Systems and Bioinformatics Laboratory, Detroit, MI, USA). Only enrichment
results with false discovery rate o0.05 were considered significant. Gene
annotation and gene ontology (GO) term enrichment for biological
processes was performed with Gene Set Enrichment Analysis (GSEA)25 for
the 289 genes with differentially expressed exons (DEEs) log2 fold change
41.5. This resulted into altogether 38 separate ontology terms with false
discovery rate o0.05. To reduce the number of GO terms, we regrouped
the related ontologies into 9 larger groups.
Statistical analyses
Data were analyzed using IBM SPSS Statistics 22.0 (IBM, Armonk, NY, USA).
P-values of o0.05 were considered statistically significant and all P-values
are two tailed. The χ2 test was used to assess the differences in the
frequency of the prognostic factors. Cox univariate and multivariate
analyses were performed to study the prognostic value of the factors.
Kaplan–Meier method was used to estimate survival rates and their
differences were compared with log-rank test. Overall survival (OS) was
determined from the date of study entry or diagnosis until the last follow-
up or death from any cause. Disease-specific survival was calculated as a
period between the registration date and the date of death due to
lymphoma. Progression-free survival (PFS) was measured as the period
between the date of registration or diagnosis and progression or death
from any cause. OS, disease-specific survival and PFS were reported in
months. A web-based cutoff finder tool at http://molpath.charite.de/cutoff
analysis26 was used to determine the most prognostic cutoff level for
survival outcomes.
Exon-specific domain identification
DEEs were annotated by their genomic locations (5′ untranslated region
(UTR), 3′ UTR, coding, noncoding and unknown). Domain analysis was
done for all coding DEEs by translating coding exonic regions into peptide
sequences using Ensembl API (version 70) and fetching domain informa-
tion (Pfam, Smart, SignalP and TMHMM) for all peptide sequences with
InterProScan (version 5).27 Phosphorylation sites within peptide sequence
of each exon were searched against all known phosphorylation motifs
downloaded from the PhosphoSitePlus.28
RESULTS
Clinical characteristics of the patients
Baseline characteristics of the discovery cohort of 38 patients
treated in the NLG-LBC-04 protocol22 are presented in Table 1.
Median age of the patients was 55 years (range 21–65 years).
During the median follow-up time of 66 months, 9 patients had
relapsed and a total of 9 died. Four of the deaths were not
lymphoma related. The estimated 5-year OS, disease-specific
survival and PFS rates were 76%, 82% and 74%, respectively. In the
CGCI validation cohort of 92 patients, the median age was 61
years (range 17–75 years). During the follow-up time of 59 months,
24 patients had relapsed and 21 died. Of the deaths, three were
not lymphoma related. The estimated 5-year OS, disease-specific
survival and PFS rates were 79%, 80% and 74%, respectively. The
main differences between the discovery and validation cohort was
Table 1. Patient characteristics of the discovery and validation
cohorts
Number of patients Discovery cohort, n (%) Validation cohort, n (%)
Total 38 (100) 92 (100)
Gender
Female 14 (37) 31 (34)
Male 24 (63) 61 (66)
Age
o60 28 (74) 39 (42)
60–65 10 (26) 15 (16)
465 0 (0) 38 (41)
Subtype
GCB 19 (50) 51 (55)
ABC 12 (32) 32 (35)
Other/unclassified 7 (18) 9 (10)
Performance status
0–1 24 (63) 64 (70)
2–3 14 (37) 28 (30)
B-symptoms 22 (58)
Bulky disease 22 (58)
Elevated LDH 37 (97)
Stage
I–II 1 (3) 44 (48)
III–IV 37 (97) 48 (52)
IPI
0 0 (0) 16 (17)
1 0 (0) 24 (26)
2 17 (45) 22 (24)
3 10 (26) 18 (20)
4 10 (26) 10 (11)
5 1 (3) 2 (2)
Abbreviations: ABC, activated B-cell; GCB, germinal center B-cell; IPI,
International Prognostic Index; LDH, lactate dehydrogenase.
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that the patients in the discovery cohort were younger and had
clinically higher risk disease (Table 1).
Identification of splicing events
Global mRNA and AS variations with prognostic impact were
identified by comparing gene and exon expression profiles
between the patients who experienced relapse (n=9, poor
prognosis group) or remained in long-term remission
(424 months;29 n=29, good prognosis group) after chemoimmu-
notherapy (Figure 1). No significant differences were observed in
baseline characteristics between the groups (Table 2). Using the
gene-level expression data, 220 differentially expressed genes
(DEGs) between the groups were identified (Supplementary
Table S1). Of these, 59% were suppressed and 41% upregulated
in patients with poor prognosis. The most upregulated genes
included not only many nonprotein coding genes such as
microRNAs and long noncoding RNAs but also MME, which is
coding for CD10 and is included in the COO classification,24
and TRAF4, which has been shown to downregulate the innate
immunity signaling.30 Innate immunity was also affected because of
suppression of other genes in the pathway such as HLA-DQB1, and
especially genes involved in T cell-mediated immune responses
(FOS, IL2RB) or B-cell maturation (IL7 and KLF3). The pathways
significantly enriched among the DEGs included immune response-
related processes, such as antigen processing and presentation,
JAK/STAT (Janus kinase/signal transducer and activator of transcrip-
tion) signaling, circadian rhythm and hematopoietic cell lineage
(Table 3 and Supplementary Table S2).
To identify AS events between the good and poor prognosis
groups, we applied similar criteria to exon-level expression data
with additional filtering of the DEGs from the gene-level analysis
(Figure 1). As a result, 8785 unique exonic regions from 3888
genes with differential expression were found (Supplementary
Table S3). Among the genes with DEEs were genes with known
alternative isoforms associated with cancer, including RUNX1,31
Figure 1. Flowchart: identification of differentially expressed genes
in DLBCL.
Table 2. Baseline characteristics of the discovery cohort according to






Total 29 (76) 9 (24)
Gender
Female 19 (66) 5 (56) 0.699
Male 10 (34) 4 (44)
Age
o60 23 (79) 6 (67) 0.655
460 6 (21) 3 (33)
Subtype
GCB 17 (59) 7 (88) 0.438
Non-GCB 12 (41) 2 (22)
Performance status
0–1 20 (69) 4 (44) 0.245
2–3 9 (31) 5 (56)
B-symptoms
No 10 (34) 6 (67) 0.128
Yes 19 (66) 3 (33)
Bulky disease
No 13 (45) 3 (33) 0.706
Yes 16 (55) 6 (67)
Elevated LDH
No 0 (0) 1 (11) 0.237
Yes 29 (100) 8 (89)
Stage
I–II 1 (3) 0 (0) 1.000
III–IV 28 (97) 9 (100)
aaIPI
3–4 21 (72) 6 (67) 1.000
8 (28) 3 (33)
BCL2
Low 27 (93) 7 (78) 0.233
Higha 2 (7) 2 (22)
cMYC
Low 28 (97) 9 (100) 1.000
High 1 (3) 0 (0)
Abbreviations: aaIPI, age-adjusted International Prognostic Index; GCB,
germinal center B-cell; LDH, lactate dehydrogenase. aZ-score 42.0.
Table 3. Pathways significantly enriched among the DEGs and DEEs





Antigen processing and presentation 2/89 o0.001
Circadian rhythm 2/13 o0.001
JAK/STAT signaling pathway 7/155 0.001
Hematopoietic cell lineage 5/87 0.003
Biosynthesis of unsaturated fatty acids 3/22 0.004
Exon level (top 20 pathways)
Antigen processing and presentation 17/89 o0.001
Leukocyte transendothelial migration 22/119 o0.001
Cell adhesion molecules (CAMs) 26/134 o0.001
Adherens junction 19/78 o0.001
Phosphatidylinositol signaling system 21/76 o0.001
ECM receptor interaction 33/84 o0.001
Focal adhesion 59/203 o0.001
Pathways in cancer 84/330 o0.001
Calcium signaling pathway 50/182 o0.001
ABC transporters 19/44 o0.001
MAPK signaling pathway 64/272 o0.001
Long-term depression 25/75 o0.001
Tight junction 36/135 o0.001
Amyotrophic lateral sclerosis (ALS) 19/56 0.001
Small cell lung cancer 25/86 0.001
VEGF signaling pathway 22/74 0.002
Axon guidance 33/129 0.002
Type I diabetes mellitus 14/44 0.002
Regulation of actin cytoskeleton 47/217 0.003
Thyroid cancer 11/29 0.003
Abbreviations: ABC, adenosine triphosphate-binding cassette; ECM, extra-
cellular matrix; DEE, differentially expressed exon; DEG, differentially
expressed gene; FDR, false discovery rate; JAK/STAT, Janus kinase/signal
transducer and activator of transcription; MAPK, mitogen-activated protein
kinase; VEGF, vascular endothelial growth factor.
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TERT32,33 and VEGFA,34 as well as CD44 and PTPRO that have
previously been shown to be alternatively spliced in
DLBCL.17,19,20,35 In the case of CD44, differential exon inclusion
was seen particularly in the variable region of the gene (exons
v2–v10), involved in variant isoforms of CD44 that have been
shown to substantiate to poor prognosis in DLBCL in the pre-
rituximab era.18,21 In the PTPRO gene, the DEE was localized in the
catalytic domain region, present also in the lymphoid-
predominant truncated isoform, shown to modulate SYK phos-
phorylation and B-cell receptor activity.36 Other genes with the
most suppressed exon expression in the poor prognosis group
included EPN1 and ARAP1, which are involved in endocytosis, and
HLA-DQA1, CD4, EBI3, ICAM1 and UBA5, which are related to the
immune system. Differential splicing was also observed in many
splicing factors and regulators, such as NOVA1, TRA2B, SF3B1,
ESRP1, RBFOX1 and CELF5, suggesting that the splicing mechanism
Figure 2. Clustering of the patients according to differentially expressed genes or exons. (a) A total of 220 DEGs and 315 DEEs were used
for clustering the DLBCL patients who relapsed or patients who remained in remission. (b) A total of 1045 DEGs and 590 DEEs were used for
clustering the ABC and GCB subgroups.
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might be affected through modulation of splicing factors
themselves. In line with the pathways significantly enriched
among the DEGs, the AS genes were significantly enriched for
immune response-related pathways, such as antigen processing
and presentation, and leukocyte transendothelial migration. In
addition, the AS genes were enriched for the pathways related to
adhesion, extracellular matrix interactions and signal transduction
such as phosphatidylinositol signaling system and adenosine
triphosphate (ATP)-binding cassette transporters (Table 3).
Interestingly, when the patient groups with poor and favorable
outcomes were clustered according to the DEGs and DEEs, the
expression profile of the most variable exons showed better
separation of the groups than the profile of the most variable
genes (Figure 2a). This indicates that AS plays an important role in
DLBCL pathogenesis.
Gene- and exon-level profiles according to COO subtypes
The observed differences in gene and exon levels between the
patient groups with different outcomes raised the question of
whether a similar phenomenon occurs when the patients are
divided according to their molecular subtypes. When the gene
expression-based COO classification was performed using pre-
viously described gene predictor,24 19 of the cases were predicted
as GCB, 12 as ABC and 7 as other DLBCL subtypes (Supplementary
Figure S1). In this cohort, no significant association between the
molecular subtypes and survival was found (not shown). With
similar criteria as previously used in the screen for the outcome-
related DEGs and genes with DEEs, 1012 unique DEGs
(Supplementary Table S4) and 20 386 exonic regions from 6726
unique genes (Supplementary Table S5) were discovered to be
differentially expressed between the GCB and the ABC DLBCLs. As
expected, the DEGs included many of the genes used in the
‘Wright’ subtype classification (SERPINA9, MYBL1, FUT8, IRF4), as
well as other genes (FOXP1, MAPK10) shown to have subtype
preferential expression profile.37,38 On the contrary, the DEEs
corresponded for only two genes (CCND2, DDB1) used in the
subtype classification. In the pathway analysis, the genes from
differential gene expression and exon usage between GCB and
ABC subtypes were enriched in, for instance, phosphatidylinositol
signaling system, regulation of actin cytoskeleton, adherens
junction, focal adhesion and pathways in cancer (Supplementary
Table S6). Altogether, the number of DEGs and DEEs was higher in
the COO classification than in the survival-related profiles.
Clustering of the patient groups with molecular subtypes
according to the DEGs or DEEs was able to separate the ABC
and GCB subtypes (Figure 2b).
Functional relevance of the alternative splicing
To analyze in more detail the functional effect of the DEEs
identified from the comparison of the groups with poor and
Figure 3. Distribution of the splicing events and characteristics of the target exons. (a) Distribution and domain involvement of the target
exons. (b) Relative distribution of the target exons by Gene Ontology (GO) categories. Representative genes from each group are presented
next to the pie chart.
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favorable outcomes, we studied the association of the exonic
regions with their corresponding protein domains using our exon-
specific functional analysis pipeline. Altogether, 49% (4351) of the
AS-related exons were protein coding, whereas 12% were mapped
to 5′ UTR, 7% to the 3′ UTR and 32% to other noncoding regions
(Figure 3a and Supplementary Table S7). Domain prediction
showed 28% of translated exons (1193) to include a functional
protein domain. In addition, 18% of the coding exons were
predicted to include phosphorylation sites, of which 53% were
serines, 25% treonines and 22% tyrosines (not shown).
In order to define the biological functions potentially affected
by AS, we performed GO annotations for biological processes with
the genes with most differentially expressed exons (log2 fold
change ⩾ ∣1.5∣, n= 289). To reduce the redundancy among several
categories, related ontologies were regrouped into larger groups
(Figure 3b). From the separate ontologies, the highest number of
genes was annotated to signal transduction (for example, SMAD5
and BCAR1). After regrouping, different cellular metabolic pro-
cesses formed the most commonly implicated processes
(for example, RAD17 and TRAF1). Transport and localization
annotation included, for example, EPN1 that is involved in
receptor-mediated endocytosis39 and ATP-binding cassette trans-
porters ABCA2, ABCA3 and ABCA7 that are mostly known for their
role in evolving drug resistance.40 Closer examination of ATP-
binding cassette transporters revealed that many of the affected
exons included a predicted functional protein domain or
phosphorylation sites (not shown), suggesting that AS events
might affect drug resistance by regulating the function and
activity of the ATP-binding cassette transporters.
Validation of exon inclusion events
To validate the outcome-associated DEEs, we used data from a
publicly available CGCI (RNAseq cohort of 92 patients).8 Of the
3888 AS genes, 547 were validated in the CGCI cohort. Thirty-
seven DEEs (33 unique genes), corresponding to 17 protein coding
transcripts, were exactly in the same location with the expression
difference in the same direction (Supplementary Table S8).
According to Cox univariate analysis, 29 out of the 37 DEEs were
associated with PFS (P⩽ 0.05) and 20 with OS in the CGCI cohort
(Table 4). In Cox multivariate analyses with International Prog-
nostic Index score, 22 DEEs retained independence for prediction
of PFS (Supplementary Table S9). These included several interest-
ing genes, such as BCAR1 (coding for p130Cas, a docking protein
involved in many intracellular signaling pathways), APH1A (anterior
pharynx defective-1α, a component of the γ-secretase complex that
cleaves integral membrane proteins such as Notch receptors and
β-amyloid precursor protein), KCNH6 (member of a potassium
voltage-gated channel family, shown to be associated with drug
sensitivity) and CUL3 (cullin 3, a core component of an E3 ubiquitin
ligase complex).
Table 4. Cox univariate analysis of the DEEs common in the discovery and validation cohorts (significant Po0.05 are in bold)
Gene Discovery cohort Validation cohort
PFS OS PFS OS
P-val exon P-val gene P-val exon P-val gene P-val exon P-val gene P-val exon P-val gene
CUL3 0.070 0.975 0.167 0.728 0.007 0.393 0.024 0.399
DKK3 0.091 0.330 0.099 0.427 0.037 0.497 0.064 0.623
BCAR1 0.022 0.179 0.108 0.499 0.005 0.439 0.002 0.449
SLC9A3 0.112 0.154 0.084 0.016 0.002 0.164 0.002 0.139
GAL 0.051 0.938 0.468 0.475 0.003 0.687 0.033 0.659
ABCB1 0.116 0.525 0.204 0.806 0.019 0.343 0.045 0.895
NAMPT 0.016 0.757 0.138 0.401 0.015 0.003 0.121 0.004
CUBN 0.035 0.285 0.038 0.246 0.047 0.024 0.079 0.018
APH1A 0.048 0.123 0.039 0.043 o0.001 0.011 o0.001 0.016
SSUH2 0.010 0.201 0.015 0.113 0.022 0.396 0.400 0.094
RHOT1 0.099 0.597 0.126 0.610 0.001 0.023 0.002 0.027
NHSL1 0.012 0.732 0.037 0.700 o0.001 0.153 0.007 0.354
TACC2 0.091 0.973 0.177 0.728 0.002 0.183 0.087 0.245
FRAS1 0.002 0.039 0.001 0.051 0.001 0.107 0.033 0.085
PTPRQ 0.013 0.862 0.170 0.861 0.130 0.404 0.018 0.032
CYP4B1 0.051 0.327 0.054 0.150 0.013 0.269 0.136 0.268
HMGCLL1 0.030 0.060 0.597 0.299 0.011 0.834 0.023 0.395
FAM83A 0.018 0.207 0.002 0.348 0.003 0.865 0.029 0.671
CPB1 0.020 0.330 0.024 0.228 0.006 0.394 0.002 0.185
SORBS2 0.104 0.418 0.285 0.962 0.101 0.151 0.417 0.149
C2orf65 0.042 0.273 0.361 0.583 o0.001 0.238 0.010 0.173
CAMK2N1 0.011 0.433 0.009 0.794 0.489 0.028 0.986 0.094
NOS3 0.022 0.246 0.031 0.687 0.034 0.753 0.064 0.760
KCNH6 0.015 0.019 0.080 0.008 0.001 0.050 0.001 0.002
TRIML2 0.005 0.005 0.008 0.003 0.015 0.338 0.019 0.859
MAP3K15 0.011 0.024 0.142 0.025 0.001 0.578 0.003 0.217
TMEM232 0.030 0.359 0.172 0.298 0.001 0.034 0.001 0.003
CYHR1 0.041 0.167 0.086 0.019 0.001 0.724 0.001 0.586
VEPH1 0.125 0.092 0.282 0.04 o0.001 0.025 0.006 0.062
AC018705.5 0.013 0.061 0.012 0.045 0.018 0.920 0.078 0.876
SPANXA2_OT1 0.029 0.048 0.151 0.076 0.124 0.053 0.153 0.200
RP11_69C17.1 0.007 0.400 0.029 0.636 0.012 0.246 0.131 0.561
RP11_696N14.1 0.068 0.160 0.614 0.447 0.017 0.982 0.190 0.691
Abbreviations: DEE, differentially expressed exon; OS, overall survival; PFS, progression-free survival.
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Some of the validated survival-associated DEEs that targeted
protein coding regions could be linked to their protein-level
functions. For example, the first coding exon of APH1A
overexpressed in patients with poor prognosis corresponded to
the entire first APH-1 transmembrane domain (Figure 4a).
Similarly, the exon with differential expression in the KCNH6 gene
Figure 4. Differentially expressed exons may affect the functional properties of the protein and are associated with survival. (a–c) The upper
panels show the domain information, the middle panels show the exon and gene expression in the discovery and validation cohorts and the
lower panels show Kaplan–Meier survival plots of the exons in DLBCL patients (validation cohort).
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mapped to the amino acids 226–367 including three transmem-
brane helix regions, and exon skipping was associated with better
survival (Figure 4b). This suggests that differential coding exon
usage could alter the protein functions and thus result in drug
resistance and disease progression. On the contrary, ABCB1
represents a gene, where exon 2 skipping occurring in the
promoter region is an unfavorable event and correlates with poor
survival (Figure 4c).
DISCUSSION
There has been an increasing interest in studying whole genome-
level alterations in DLBCL during the recent years.9 The contribu-
tion of these studies in the identification of key elements in DLBCL
pathogenesis has been crucial, yet the impact of AS on DLBCL
pathogenesis and survival has to date remained largely unex-
plored. In this work, we have performed microarray-based exon
and whole transcriptome profiling on freshly frozen lymphoma
tissue collected prospectively from DLBCL patients treated
homogenously in a Nordic phase II study.22 We show association
of AS genes with molecular subtypes and survival. Interestingly,
exon-level profile can separate clinically high-risk DLBCL patients
into subgroups with poor and favorable survival more accurately
than gene-level profile. We observe that many of the genes are
differentially expressed only at the exon level but not at the gene
level and would have been missed if only gene-level analysis or
conventional 3′ oligonucleotide microarrays had been used.
Finally, we validate molecular subtype and survival association
of the key DEGs and DEEs in an independent DLBCL cohort. Our
observations provide important basis for understanding the
mechanisms of DLBCL pathogenesis and prognosis, and develop-
ment of novel therapeutic strategies.
Approximately half of the AS events target noncoding regions.
A significant proportion of the alterations affected 5′ and 3′ UTRs,
suggesting modulation of epigenetic regulatory pathways in
DLBCL. Although alternative exon usage in the coding regions can
generate different protein isoforms, splicing in the noncoding 3′
UTRs can compromise microRNA-dependent gene regulation and
change the composition of translational regulatory elements, or
result in differential promoter usage in 5′ UTRs that in turn can
further alter protein expression.41 Moreover, the upstream
promoter site may be selectively affected and differential
promoter usage produce N-terminal splice variants.42 Our results
further suggest that the splicing mechanism might be affected
through modulation of splicing factors themselves, providing yet
another regulatory level for gene expression.
A novel finding from the pathway analysis of the DEGs was the
enrichment of the genes in the circadian rhythm pathway.
Disturbances of the mammalian clock genes have been linked
to tumorigenesis. In DLBCL, circadian genes CEBPA and its
downstream target PER2 are highly deregulated,43 and BMAL1
(ARNTL) is epigenetically inactivated.44 Furthermore, genetic
variants of CRY2 have been associated with a risk of non-
Hodgkin’s lymphoma. In our exon array results, the expression of
the circadian clock genes PER1 and ARNTL was reduced in relapsed
patients and thus associated with dismal prognosis.
ATP-binding cassette transporters, in turn, represent a novel
group of genes we found to be regulated at the exon level and
thereby potentially affected by AS. To date, ATP-binding cassette
transporters have been mostly recognized from their contribution
to drug resistance. The highly conserved ATP-binding cassette
domains of these transporters provide the ATP-powered translo-
cation of many substrates across the membranes, whereas the
transmembrane domains creating the translocation pathway are
more variable. According to our domain prediction analysis of
splicing-associated ATP-binding cassette transporters, many of the
affected domains included either a transmembrane domain or an
ATP-binding cassette domain that might directly have an effect to
the proper function of the transporter. Most of the AS-associated
ATP-binding cassette transporters belonged to ABCA family. These
included genes encoding ABCA2 and ABCA3 that have been
shown to contribute to drug resistance in T-cell acute lympho-
blastic leukemia.45 In addition, increased expression of ABCA3 has
been linked to enhanced exosomal evasion of humoral
immunotherapy.46
We validated the DEGs and DEEs in an independent patient
cohort consisting of RNAseq data. APH1A was one of the
interesting examples of the AS genes that could be validated by
RNAseq and linked to protein-level functions. It encodes an
essential component of the multi-transmembrane γ-secretase
complex that is required for the cleavage and activation of integral
membrane proteins, including Notch.47 Considering the increasing
Figure 4. Continued.
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evidence of the deregulated Notch signaling in cancer progres-
sion, γ-secretases playing an important role in Notch activation
and that APH1A is critically required for γ-secretase activity, our
finding showing that alternative exon usage of APH1A gene has
prognostic impact in DLBCL may have therapeutic implications.
Thus, future studies should be directed to enhance our under-
standing of the function of APH1A isoforms and their relation to
Notch signaling in DLBCL that may further improve opportunities
for the design of selective lymphoma therapeutics.
KCNH6, also known as HERG2, encodes a pore-forming subunit
of a voltage-gated potassium channel. Potassium channels
comprise the largest family of ion channels encoded by genes
with phenotypic diversity generated through alternative splicing,
variable association of channel subunits and posttranslational
modifications. Recent data indicate that blocking of the ion
channel activity can impair cancer cell growth.48 Interestingly,
HERG potassium channels are constitutively active in acute
myeloid leukemia,49,50 and have favorable prognostic impact on
survival. In our study, no differences were observed in HERG2 gene
expression levels between poor and good prognosis patients.
However, low expression of exon 5, which corresponds to the first
transmembrane and ion transport domains, was associated with
favorable survival. The result suggests that these functional
domains mediate prosurvival signals that can be overcome by
exon 5 skipping. ABCB1 in turn represents a gene where exon 2
skipping occurring in the promoter region is an unfavorable event
correlating with lymphoma progression.
Taken together, the results presented herein are promising and
novel, and suggest a significant role for alternative exon usage in
the molecular profiles of DLBCL. The importance of studying
connections between splicing and DLBCL is emphasized by the
possibility that some AS isoforms drive progression and may
represent attractive therapeutic targets even if total gene
expression is not affected. Moreover, unique or sets of isoforms
may be used as biomarkers for disease progression.
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